The Peptide That “Changes Everything” with Andrew Huberman

Summary

Andrew Huberman joins TBPN to discuss caffeine and performance, Olympic athletes' legal edges, the gray-market peptide boom, cannabis risks, social media brain rot, and his use of AI. The main market-relevant takeaway is his bullish view on Eli Lilly's retatrutide as a potential trillion-dollar weight-loss drug. Most other topics are health, supplement, and behavioral commentary without a directly named public security.

• Huberman discusses caffeine as a performance enhancer and his Matina yerba mate business.
• Olympic athletes use vasodilators and other non-banned compounds for performance.
• Gray-market peptides like BPC-157 and retatrutide are popular, with purity and legal risks.
• Eli Lilly's patented retatrutide showed up to one-third body weight loss in Phase 3.
• Cannabis high-THC use is linked to psychosis, addiction, and REM sleep disruption.
• Social media short-form video can cause brain rot; Huberman recommends limiting screen time.
• Huberman uses Claude for learning and AI features in Eight Sleep.
• The interview closes with personal topics like aquariums and bulldogs.